Thiol-disulfidestatus of patients with cervical cancer
Özet
Aim The evaluation of dynamic thiol-disulfide homeostasis among patients with the cancer of the uterine cervix. Methods The study was conducted in 62 cervical cancer patients and 61 healthy women who had been followed up in an obstetrics and gynecology clinic between September 2018 and April 2020. Serum disulfide, native thiol, total thiol, ischemia modified-albumin, total antioxidant and oxidant capacities, and oxidative stress index values were measured in all participants. Results The mean plasma disulfide levels of the cervical cancer group was statistically significantly higher than that of the control group (25.79 +/- 6.90 mu mol/L, 22.31 +/- 6.11 mu mol/L, respectively) (P= 0.004). Plasma native thiol and total thiol levels were lower in cervical cancer patients (299.27 +/- 99.05 mu mol/L and 350.86 +/- 102.72 mu mol/L, respectively) compared to controls, but no statistically significant difference was observed (318.00 +/- 93.75 mu mol/L and 376.44 +/- 98.51 mu mol/L, respectively) (P= 0.284,P= 0.161). With respect to the ischemia modified-albumin level, no statistically significant difference was observed between two groups. There were statistically significant positive association between disulfide level and both the stage of cervical cancer (r= 0.278,P= 0.029) and total oxidant capacity level (r= 0.256,P= 0.046). Conclusion Dynamic thiol-disulfide homeostasis may participate in the pathophysiological mechanisms of cervical cancer and may be a potential biomarker for early identification of cervical cancer in future.
